Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte, a Nasdaq-listed biotechnology company focused on bioengineered human tissues, has commenced an underwritten public offering of its common stock to raise funds for commercializing its FDA-approved product Symvess, filing a BLA supplement for hemodialysis, advancing pipeline product candidates, and for general corporate purposes. The offeri…